Lancet

The most recent articles from: Lancet October 2023

Lancet · Oct 2023

Editorial

Offline: Israel-Gaza-what comes next?

no abstract available

expand abstract… or not…
Lancet · Oct 2023

Comment

Changing the landscape of surgery for simple appendicitis.

no abstract available

explore further… or not…
Lancet · Oct 2023

Department of Error.

no abstract available

keep going… or not…
Lancet · Oct 2023

Randomized Controlled Trial Multicenter Study

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. ⋯ Boehringer Ingelheim.

read on… or not…
Lancet · Oct 2023

The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.

no abstract available

read on… or not…

1
2
3
4
5
6
7
8
9
…
26
27

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.